Not A Moment Too Soon

Target Audience

The educational design of this activity addresses the needs of primary care physicians, nurse practitioners, physician assistants, and nurses related to optimizing early detection of multiple cancer types.

Program Overview

Blood-based multi-cancer early detection (MCED) tests have demonstrated the ability to identify specific genetic markers from tumors at early stages of cancer development. Thus, this technology has the potential to reduce the burden of cancer and improve patient outcomes by detecting cancer at its earliest stages, allowing treatment to begin sooner than when a cancer is identified based on symptomatic presentations. In addition, earlier detection may also help reduce the costs and complexity of cancer treatment, minimize morbidity, and improve mortality rates and quality of life. This program will discuss the current burdens of cancer in the United States, the science behind MCED tests, and offer practical suggestions for potential incorporation of MCED screening into primary care practice.

Educational Objectives

After completing this activity, the participant should be better able to:

• Describe the current incidence, guideline-recommended screening rates, and disease burden of cancer in the United States
• Explain the role of blood-based biomarkers, especially cell-free DNA (cfDNA), in MCED tests and their potential role in improving early detection rates
• Summarize recent clinical trial and real-world data of available and emerging MCED tests, including their accuracy, benefits, limitations, and cost-effectiveness
• Incorporate MCED testing into primary care practice, including relevant patient counseling, shared decision-making, and follow-up care pathways when a result is positive

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Integritas Contact Information

For more information about the approval (ACCME credit) of this program, please contact Integritas at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score at least 75% on the posttest and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas.  All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty has the following relevant financial relationships with ineligible companies:

Richard A. Whittington, MD: Nothing to disclose

The planners and managers have no relevant financial relationships with ineligible companies.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.